Back to Search
ROBERTA SALAZAR, MD
MD
Pediatrics Physician
NPI: 1235287194Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
A54858(CA)
Research & Publications (20)
BRCA1-2 mutations in breast cancer: identification of nine new variants of BRCA1-2 genes in a population from central Western Spain.
PMID 15876480·Cancer Lett·2006
8-other
Antimicrobial activity of coupled hydroxyanthracenones isolated from plants of the genus Karwinskia.
PMID 16797144·Fitoterapia·2006
8-other
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
PMID 15240525·Clin Cancer Res·2004
3-trial
Synchronization of surface reactions via Turing-like structures.
PMID 15089301·Phys Rev E Stat Nonlin Soft Matter Phys·2004
8-other
Binding of Amadori glucose-modified albumin by the monocytic cell line MonoMac 6 activates protein kinase C epsilon protein tyrosine kinases and the transcription factors AP-1 and NF-kappaB.
PMID 12441666·Glycoconj J·2001
8-other
Role of CD4:CD8 ratio in predicting HIV co-infection in patients with newly diagnosed tuberculosis.
PMID 10743519·AIDS Patient Care STDS·2000
8-other
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
PMID 19370414·Breast Cancer Res Treat·2010
8-other
PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts.
PMID 19586538·Mol Cancer·2009
8-other
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.
PMID 19423537·Cancer Epidemiol Biomarkers Prev·2009
4-observational
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.
PMID 19002188·Br J Cancer·2008
7-preclinical
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
PMID 18335219·Cancer Chemother Pharmacol·2008
3-trial
Differences in patient postoperative and long-term outcomes between obstructive and perforated colonic cancer.
PMID 18361923·Am J Surg·2008
4-observational
Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
PMID 18281545·Clin Cancer Res·2008
3-trial
Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia.
PMID 18186055·Am J Med Genet B Neuropsychiatr Genet·2008
8-other
Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis.
PMID 18334708·J Natl Cancer Inst·2008
1-meta
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
PMID 18451254·Clin Cancer Res·2008
4-observational
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
PMID 18172273·Clin Cancer Res·2008
3-trial
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.
PMID 18437204·PLoS Genet·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 441 N LAKEVIEW AVE
ANAHEIM, CA 92807 - Phone
- (888) 988-2800
Quick Facts
- NPI
- 1235287194
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile